A citation-based method for searching scientific literature

Špela Gubič, Louise A Hendrickx, Žan Toplak, Maša Sterle, Steve Peigneur, Tihomir Tomašič, Luis A Pardo, Jan Tytgat, Anamarija Zega, Lucija P Mašič. Med Res Rev 2021
Times Cited: 9







List of co-cited articles
70 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases.
Christine Beeton, Heike Wulff, Nathan E Standifer, Philippe Azam, Katherine M Mullen, Michael W Pennington, Aaron Kolski-Andreaco, Eric Wei, Alexandra Grino, Debra R Counts,[...]. Proc Natl Acad Sci U S A 2006
412
44

The voltage-gated potassium channel KV1.3 as a therapeutic target for venom-derived peptides.
Gabor Tajti, Dorothy C C Wai, Gyorgy Panyi, Raymond S Norton. Biochem Pharmacol 2020
25
44

Treating autoimmune disorders with venom-derived peptides.
Bingzheng Shen, Zhijian Cao, Wenxin Li, Jean-Marc Sabatier, Yingliang Wu. Expert Opin Biol Ther 2017
33
44

A unified nomenclature for short-chain peptides isolated from scorpion venoms: alpha-KTx molecular subfamilies.
J Tytgat, K G Chandy, M L Garcia, G A Gutman, M F Martin-Eauclaire, J J van der Walt, L D Possani. Trends Pharmacol Sci 1999
337
44

Ion channels in innate and adaptive immunity.
Stefan Feske, Heike Wulff, Edward Y Skolnik. Annu Rev Immunol 2015
368
44

An engineered scorpion toxin analogue with improved Kv1.3 selectivity displays reduced conformational flexibility.
Adam Bartok, Krisztina Fehér, Andrea Bodor, Kinga Rákosi, Gábor K Tóth, Katalin E Kövér, Gyorgy Panyi, Zoltan Varga. Sci Rep 2015
15
44

Kv1.3 Channel as a Key Therapeutic Target for Neuroinflammatory Diseases: State of the Art and Beyond.
Xiaoli Wang, Guoyi Li, Jingkang Guo, Zhiping Zhang, Shuzhang Zhang, Yudan Zhu, Jiwei Cheng, Lu Yu, Yonghua Ji, Jie Tao. Front Neurosci 2020
33
44

Voltage-Gated Potassium Channel Kv1.3 as a Target in Therapy of Cancer.
Andrzej Teisseyre, Anna Palko-Labuz, Kamila Sroda-Pomianek, Krystyna Michalak. Front Oncol 2019
34
33


On the convergent evolution of animal toxins. Conservation of a diad of functional residues in potassium channel-blocking toxins with unrelated structures.
M Dauplais, A Lecoq, J Song, J Cotton, N Jamin, B Gilquin, C Roumestand, C Vita, C L de Medeiros, E G Rowan,[...]. J Biol Chem 1997
280
33

The voltage-gated potassium channel Kv1.3 is a promising multitherapeutic target against human pathologies.
Mireia Pérez-Verdaguer, Jesusa Capera, Clara Serrano-Novillo, Irene Estadella, Daniel Sastre, Antonio Felipe. Expert Opin Ther Targets 2016
54
33

Voltage-gated potassium channels as therapeutic targets.
Heike Wulff, Neil A Castle, Luis A Pardo. Nat Rev Drug Discov 2009
511
33

Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
S Grissmer, A N Nguyen, J Aiyar, D C Hanson, R J Mather, G A Gutman, M J Karmilowicz, D D Auperin, K G Chandy. Mol Pharmacol 1994
696
33

The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS.
Heike Wulff, Peter A Calabresi, Rameeza Allie, Sung Yun, Michael Pennington, Christine Beeton, K George Chandy. J Clin Invest 2003
346
33

The 'functional' dyad of scorpion toxin Pi1 is not itself a prerequisite for toxin binding to the voltage-gated Kv1.2 potassium channels.
Stéphanie Mouhat, Amor Mosbah, Violeta Visan, Heike Wulff, Muriel Delepierre, Hervé Darbon, Stephan Grissmer, Michel De Waard, Jean-Marc Sabatier. Biochem J 2004
62
33

A potent and Kv1.3-selective analogue of the scorpion toxin HsTX1 as a potential therapeutic for autoimmune diseases.
M Harunur Rashid, Redwan Huq, Mark R Tanner, Sandeep Chhabra, Keith K Khoo, Rosendo Estrada, Vikas Dhawan, Satendra Chauhan, Michael W Pennington, Christine Beeton,[...]. Sci Rep 2014
58
33

A four-disulphide-bridged toxin, with high affinity towards voltage-gated K+ channels, isolated from Heterometrus spinnifer (Scorpionidae) venom.
B Lebrun, R Romi-Lebrun, M F Martin-Eauclaire, A Yasuda, M Ishiguro, Y Oyama, O Pongs, T Nakajima. Biochem J 1997
95
33

Structure of a pore-blocking toxin in complex with a eukaryotic voltage-dependent K(+) channel.
Anirban Banerjee, Alice Lee, Ernest Campbell, Roderick Mackinnon. Elife 2013
143
33

A variable residue in the pore of Kv1 channels is critical for the high affinity of blockers from sea anemones and scorpions.
Bernard Gilquin, Sandrine Braud, Mats A L Eriksson, Benoît Roux, Timothy D Bailey, Birgit T Priest, Maria L Garcia, André Ménez, Sylvaine Gasparini. J Biol Chem 2005
40
33

A selective blocker of Kv1.2 and Kv1.3 potassium channels from the venom of the scorpion Centruroides suffusus suffusus.
Gerardo Corzo, Ferenc Papp, Zoltan Varga, Omar Barraza, Pavel G Espino-Solis, Ricardo C Rodríguez de la Vega, Rezso Gaspar, Gyorgy Panyi, Lourival D Possani. Biochem Pharmacol 2008
39
33

Vm24, a natural immunosuppressive peptide, potently and selectively blocks Kv1.3 potassium channels of human T cells.
Zoltan Varga, Georgina Gurrola-Briones, Ferenc Papp, Ricardo C Rodríguez de la Vega, Gustavo Pedraza-Alva, Rajeev B Tajhya, Rezso Gaspar, Luis Cardenas, Yvonne Rosenstein, Christine Beeton,[...]. Mol Pharmacol 2012
65
33

Scorpion venom components that affect ion-channels function.
V Quintero-Hernández, J M Jiménez-Vargas, G B Gurrola, H H Valdivia, L D Possani. Toxicon 2013
169
33

Solution structure of ShK toxin, a novel potassium channel inhibitor from a sea anemone.
J E Tudor, P K Pallaghy, M W Pennington, R S Norton. Nat Struct Biol 1996
144
22

Toxin acidic residue evolutionary function-guided design of de novo peptide drugs for the immunotherapeutic target, the Kv1.3 channel.
Zongyun Chen, Youtian Hu, Jing Hong, Jun Hu, Weishan Yang, Fang Xiang, Fan Yang, Zili Xie, Zhijian Cao, Wenxin Li,[...]. Sci Rep 2015
25
22

ShK-Dap22, a potent Kv1.3-specific immunosuppressive polypeptide.
K Kalman, M W Pennington, M D Lanigan, A Nguyen, H Rauer, V Mahnir, K Paschetto, W R Kem, S Grissmer, G A Gutman,[...]. J Biol Chem 1998
212
22

Unusual binding mode of scorpion toxin BmKTX onto potassium channels relies on its distribution of acidic residues.
Zongyun Chen, Youtian Hu, Jun Hu, Weishan Yang, Jean-Marc Sabatier, Michel De Waard, Zhijian Cao, Wenxin Li, Song Han, Yingliang Wu. Biochem Biophys Res Commun 2014
29
22

Lymphocyte activation in type 1 diabetes mellitus: the increased significance of Kv1.3 potassium channels.
Gergely Toldi, Barna Vásárhelyi, Ambrus Kaposi, Gergo Mészáros, Pál Pánczél, Nóra Hosszufalusi, Tivadar Tulassay, András Treszl. Immunol Lett 2010
29
22


From Animal Poisons and Venoms to Medicines: Achievements, Challenges and Perspectives in Drug Discovery.
Karla de Castro Figueiredo Bordon, Camila Takeno Cologna, Elisa Corrêa Fornari-Baldo, Ernesto Lopes Pinheiro-Júnior, Felipe Augusto Cerni, Fernanda Gobbi Amorim, Fernando Antonio Pino Anjolette, Francielle Almeida Cordeiro, Gisele Adriano Wiezel, Iara Aimê Cardoso,[...]. Front Pharmacol 2020
58
22

Toxin-induced conformational changes in a potassium channel revealed by solid-state NMR.
Adam Lange, Karin Giller, Sönke Hornig, Marie-France Martin-Eauclaire, Olaf Pongs, Stefan Becker, Marc Baldus. Nature 2006
318
22

Peptide blockers of Kv1.3 channels in T cells as therapeutics for autoimmune disease.
K George Chandy, Raymond S Norton. Curr Opin Chem Biol 2017
62
22

Emerging role for the voltage-dependent K+ channel Kv1.5 in B-lymphocyte physiology: expression associated with human lymphoma malignancy.
Albert Vallejo-Gracia, Joanna Bielanska, Javier Hernández-Losa, Josep Castellví, M Carmen Ruiz-Marcellan, Santiago Ramón y Cajal, Enric Condom, Joan Manils, Concepció Soler, Núria Comes,[...]. J Leukoc Biol 2013
25
22

Kv1.3 inhibition as a potential microglia-targeted therapy for Alzheimer's disease: preclinical proof of concept.
Izumi Maezawa, Hai M Nguyen, Jacopo Di Lucente, David Paul Jenkins, Vikrant Singh, Silvia Hilt, Kyoungmi Kim, Srikant Rangaraju, Allan I Levey, Heike Wulff,[...]. Brain 2018
49
22


K+ channel types targeted by synthetic OSK1, a toxin from Orthochirus scrobiculosus scorpion venom.
Stéphanie Mouhat, Violeta Visan, S Ananthakrishnan, Heike Wulff, Nicolas Andreotti, Stephan Grissmer, Hervé Darbon, Michel De Waard, Jean-Marc Sabatier. Biochem J 2005
90
22

Expression of voltage-gated potassium channels Kv1.3 and Kv1.5 in human gliomas.
Katja Preussat, Christian Beetz, Michael Schrey, Robert Kraft, Stefan Wölfl, Rolf Kalff, Stephan Patt. Neurosci Lett 2003
83
22


Different residues in channel turret determining the selectivity of ADWX-1 inhibitor peptide between Kv1.1 and Kv1.3 channels.
Shi-Jin Yin, Ling Jiang, Hong Yi, Song Han, Dai-Wen Yang, Mai-Li Liu, Hui Liu, Zhi-Jian Cao, Ying-Liang Wu, Wen-Xin Li. J Proteome Res 2008
45
22

Mitochondrial Kv1.3: a New Target in Cancer Biology?
Vanessa Checchetto, Elena Prosdocimi, Luigi Leanza. Cell Physiol Biochem 2019
11
22

Characterization of a potassium channel toxin from the Caribbean Sea anemone Stichodactyla helianthus.
O Castañeda, V Sotolongo, A M Amor, R Stöcklin, A J Anderson, A L Harvey, A Engström, C Wernstedt, E Karlsson. Toxicon 1995
197
22

Identification of a new class of inhibitors of the voltage-gated potassium channel, Kv1.3, with immunosuppressant properties.
William A Schmalhofer, Jianming Bao, Owen B McManus, Brian Green, Mary Matyskiela, Denise Wunderler, Randal M Bugianesi, John P Felix, Markus Hanner, Ana-Rosa Linde-Arias,[...]. Biochemistry 2002
54
22

Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases.
Alexander Schmitz, Ananthakrishnan Sankaranarayanan, Philippe Azam, Kristina Schmidt-Lassen, Daniel Homerick, Wolfram Hänsel, Heike Wulff. Mol Pharmacol 2005
162
22

Safety and pharmacodynamics of dalazatide, a Kv1.3 channel inhibitor, in the treatment of plaque psoriasis: A randomized phase 1b trial.
Eric J Tarcha, Chelsea M Olsen, Peter Probst, David Peckham, Ernesto J Muñoz-Elías, James G Kruger, Shawn P Iadonato. PLoS One 2017
79
22

Diverse Structural Features of Potassium Channels Characterized by Scorpion Toxins as Molecular Probes.
Yonghui Zhao, Zongyun Chen, Zhijian Cao, Wenxin Li, Yingliang Wu. Molecules 2019
9
22

Voltage-dependent potassium channels Kv1.3 and Kv1.5 in human cancer.
J Bielanska, J Hernández-Losa, M Pérez-Verdaguer, T Moline, R Somoza, S Ramón Y Cajal, E Condom, J C Ferreres, A Felipe. Curr Cancer Drug Targets 2009
63
22

Inhibition of the potassium channel Kv1.3 reduces infarction and inflammation in ischemic stroke.
Yi-Je Chen, Hai M Nguyen, Izumi Maezawa, Lee-Way Jin, Heike Wulff. Ann Clin Transl Neurol 2017
28
22

Scorpion toxins targeting Kv1.3 channels: insights into immunosuppression.
Isadora S Oliveira, Isabela G Ferreira, Gabriel M Alexandre-Silva, Felipe A Cerni, Caroline M Cremonez, Eliane C Arantes, Umberto Zottich, Manuela B Pucca. J Venom Anim Toxins Incl Trop Dis 2019
13
22

Pharmacological profiling of Orthochirus scrobiculosus toxin 1 analogs with a trimmed N-terminal domain.
Stéphanie Mouhat, Georgeta Teodorescu, Daniel Homerick, Violeta Visan, Heike Wulff, Yingliang Wu, Stephan Grissmer, Hervé Darbon, Michel De Waard, Jean-Marc Sabatier. Mol Pharmacol 2006
34
22

Anuroctoxin, a new scorpion toxin of the alpha-KTx 6 subfamily, is highly selective for Kv1.3 over IKCa1 ion channels of human T lymphocytes.
Miklós Bagdány, Cesar V F Batista, Norma A Valdez-Cruz, Sándor Somodi, Ricardo C Rodriguez de la Vega, Alexei F Licea, Zoltán Varga, Rezso Gáspár, Lourival D Possani, György Panyi. Mol Pharmacol 2005
47
22

Kv1.3 potassium channels as a therapeutic target in multiple sclerosis.
Srikant Rangaraju, Victor Chi, Michael W Pennington, K George Chandy. Expert Opin Ther Targets 2009
75
22


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.